Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing immune-modulating therapies for the management and treatment of life-threatening conditions. Co.'s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. We show 17 historical shares outstanding datapoints in our ELDN shares outstanding history coverage, used to compute ELDN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ELDN market cap history over the course of time is important for investors
interested in comparing ELDN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ELDN versus a peer is one thing; comparing
ELDN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ELDN can fluctuate over the course of history.
With this page we aim to empower investors researching ELDN by allowing them to research the ELDN market cap history. |
Free ELDN Email Alerts:
Video: The Importance of Market Cap
